Emazid 10 mg (Tablet)
Unit Price: ৳ 25.00 (2 x 10: ৳ 500.00)
Strip Price: ৳ 250.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Title
- Emazid 10 mg Tablet
Categories
- Medicine
- Pharmaceutical
Function
- Improves glycemic control in adults with type 2 diabetes mellitus
- Reduces the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Dosage
- Recommended dose of 10 mg once daily
- Can be increased to 25 mg once daily in patients tolerating the medicine
- Patients with volume depletion should correct this condition prior to initiation of the medicine
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pharmacology
- Sodium glucose co-transporter-2 (SGLT-2) inhibitor
- Reduces renal absorption and lowers the renal threshold for glucose
- Contributes to reduced hyperglycemia, weight loss, and reduced blood pressure
Interactions
- Diuretics - co-administration resulted in increased urine volume
- Insulin or insulin secretagogues - co-administration increases the risk for hypoglycemia
- Positive Urine Glucose Test - monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors
- Interference with 1,5-anhydroglucitol (1,5-AG) Assay - monitoring glycemic control with 1,5-AG assay is not recommended
Contraindications
- History of serious hypersensitivity reaction to the medicine or any of its ingredients
- Severe renal impairment
- End-stage renal disease
- Dialysis
Side Effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy and Lactation
- Not enough studies available in pregnant women
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Not recommended when breastfeeding
Precautions and Warnings
- Assessment of renal function recommended prior to initiation and periodically thereafter
- Not initiated in patients with an eGFR less than 45 ml/min/1.73 m²
- No dose adjustment needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m²
Overdose Effects
- Usual supportive measures should be employed in the event of an overdose
- Removal by hemodialysis has not been studied
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Keep in a cool & dry place (below 30°C)
- Protected from light & moisture
- Keep out of the reach of children
Chemical Structure
- Molecular Formula: C23H27ClO7
Commonly Asked Questions
- Used to improve glycemic control in adults
- May be unsafe to use during pregnancy
- Unsafe to use during breastfeeding
- Should be used cautiously in patients with underlying kidney disease
- No dose adjustment needed for patients with mild to moderate liver disease
- Information on quick tips for usage and precautions